These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. Ko TM; Chung WH; Wei CY; Shih HY; Chen JK; Lin CH; Chen YT; Hung SI J Allergy Clin Immunol; 2011 Dec; 128(6):1266-1276.e11. PubMed ID: 21924464 [TBL] [Abstract][Full Text] [Related]
24. Immunogenetics of drug-induced skin blistering disorders. Part I: Perspective. Bowman C; Delrieu O Pharmacogenomics; 2009 Apr; 10(4):601-21. PubMed ID: 19374517 [TBL] [Abstract][Full Text] [Related]
25. HLA alleles and drug hypersensitivity reactions. Profaizer T; Eckels D Int J Immunogenet; 2012 Apr; 39(2):99-105. PubMed ID: 22136512 [TBL] [Abstract][Full Text] [Related]
26. New approaches for predicting T cell-mediated drug reactions: A role for inducible and potentially preventable autoimmunity. Michels AW; Ostrov DA J Allergy Clin Immunol; 2015 Aug; 136(2):252-7. PubMed ID: 26254052 [TBL] [Abstract][Full Text] [Related]
27. Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions. Chang CJ; Chen CB; Hung SI; Ji C; Chung WH Front Pharmacol; 2020; 11():969. PubMed ID: 32714190 [TBL] [Abstract][Full Text] [Related]
28. Current understanding of genetic associations with delayed hypersensitivity reactions induced by antibiotics and anti-osteoporotic drugs. Wung CH; Wang CW; Lai KC; Chen CB; Chen WT; Hung SI; Chung WH; Front Pharmacol; 2023; 14():1183491. PubMed ID: 37180708 [TBL] [Abstract][Full Text] [Related]
29. An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity. Chen CB; Abe R; Pan RY; Wang CW; Hung SI; Tsai YG; Chung WH J Immunol Res; 2018; 2018():6431694. PubMed ID: 29651444 [TBL] [Abstract][Full Text] [Related]
30. Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis. Chung WH; Hung SI J Dermatol Sci; 2012 Jun; 66(3):190-6. PubMed ID: 22541332 [TBL] [Abstract][Full Text] [Related]
31. Epidemiology of severe drug hypersensitivity. Dodiuk-Gad RP; Laws PM; Shear NH Semin Cutan Med Surg; 2014 Mar; 33(1):2-9. PubMed ID: 25037253 [TBL] [Abstract][Full Text] [Related]
32. Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice. Peter JG; Lehloenya R; Dlamini S; Risma K; White KD; Konvinse KC; Phillips EJ J Allergy Clin Immunol Pract; 2017; 5(3):547-563. PubMed ID: 28483310 [TBL] [Abstract][Full Text] [Related]
33. Immune pathomechanism of drug hypersensitivity reactions. Pichler WJ; Naisbitt DJ; Park BK J Allergy Clin Immunol; 2011 Mar; 127(3 Suppl):S74-81. PubMed ID: 21354503 [TBL] [Abstract][Full Text] [Related]
34. Pharmacogenomic Advances in the Prediction and Prevention of Cutaneous Idiosyncratic Drug Reactions. Pan RY; Dao RL; Hung SI; Chung WH Clin Pharmacol Ther; 2017 Jul; 102(1):86-97. PubMed ID: 28295240 [TBL] [Abstract][Full Text] [Related]
35. HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region. Yeo SI Int J Rheum Dis; 2013 Jun; 16(3):254-7. PubMed ID: 23981744 [TBL] [Abstract][Full Text] [Related]
36. Genetic variants associated with T cell-mediated cutaneous adverse drug reactions: A PRISMA-compliant systematic review-An EAACI position paper. Oussalah A; Yip V; Mayorga C; Blanca M; Barbaud A; Nakonechna A; Cernadas J; Gotua M; Brockow K; Caubet JC; Bircher A; Atanaskovic-Markovic M; Demoly P; Kase-Tanno L; Terreehorst I; Laguna JJ; Romano A; Guéant JL; Pirmohamed M; Allergy; 2020 May; 75(5):1069-1098. PubMed ID: 31899808 [TBL] [Abstract][Full Text] [Related]
37. Pharmacogenetic determinants of immediate and delayed reactions of drug hypersensitivity. Guéant JL; Guéant-Rodriguez RM; Gastin IA; Cornejo-García JA; Viola M; Barbaud A; Mertes PM; Blanca M; Romano A Curr Pharm Des; 2008; 14(27):2770-7. PubMed ID: 18991696 [TBL] [Abstract][Full Text] [Related]
38. Presence of the HLA-A*3101 allele in a familial case of drug reaction with eosinophilia and systemic symptoms, secondary to carbamazepine. Anjum N; Polak ME; Ardern-Jones M; Cooper HL Clin Exp Dermatol; 2014 Apr; 39(3):307-9. PubMed ID: 24635066 [TBL] [Abstract][Full Text] [Related]